Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Jun;49(6):717–722. doi: 10.1038/bjc.1984.113

Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.

A E Lykkesfeldt, J K Larsen, I J Christensen, P Briand
PMCID: PMC1976853  PMID: 6733020

Abstract

The effect of 10(-6) M tamoxifen on MCF-7 cells adapted to growth in 0.5% foetal calf serum has been studied. The growth inhibitory effect of this tamoxifen concentration was abolished by simultaneous addition of 10(-8) M oestradiol, indicating that tamoxifen may exert its effect via binding to the oestrogen receptor. Flow cytometric cell cycle analysis of tamoxifen-treated cultures showed an increase in the proportion of cells in the G1 phase of the cell cycle. By exposing the cells to BUdR before flow cytometry the growth fraction was determined and found to be dramatically decreased in tamoxifen-treated cultures. Cells were not only arrested in the G1 phase but also in the G2 phase of the cell cycle. A few colonies of MCF-7 cells were resistant to 10 days treatment with 10(-6) M tamoxifen.

Full text

PDF
717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Horwitz K. B., McGuire W. L. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem. 1978 Nov 25;253(22):8185–8191. [PubMed] [Google Scholar]
  2. Horwitz K. B., Mockus M. B., Lessey B. A. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell. 1982 Mar;28(3):633–642. doi: 10.1016/0092-8674(82)90218-5. [DOI] [PubMed] [Google Scholar]
  3. Miller L. A detergent-citric acid technique for isolating nuclear and cytoplasmic fractions containing undegraded RNA from cells of Xenopus laevis. Anal Biochem. 1979 Nov 15;100(1):166–173. doi: 10.1016/0003-2697(79)90127-1. [DOI] [PubMed] [Google Scholar]
  4. Miller M. A., Katzenellenbogen B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983 Jul;43(7):3094–3100. [PubMed] [Google Scholar]
  5. Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978 Sep;5(3):131–141. doi: 10.1016/s0305-7372(78)80017-6. [DOI] [PubMed] [Google Scholar]
  6. Nawata H., Bronzert D., Lippman M. E. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem. 1981 May 25;256(10):5016–5021. [PubMed] [Google Scholar]
  7. Osborne C. K., Boldt D. H., Clark G. M., Trent J. M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983 Aug;43(8):3583–3585. [PubMed] [Google Scholar]
  8. Rose C., Thorpe S. M., Løber J., Daenfeldt J. L., Palshof T., Mouridsen H. T. Therapeutic effect of tamoxifen related to estrogen receptor level. Recent Results Cancer Res. 1980;71:134–141. doi: 10.1007/978-3-642-81406-8_19. [DOI] [PubMed] [Google Scholar]
  9. Sutherland R. L., Green M. D., Hall R. E., Reddel R. R., Taylor I. W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983 May;19(5):615–621. doi: 10.1016/0277-5379(83)90177-3. [DOI] [PubMed] [Google Scholar]
  10. Sutherland R. L., Murphy L. C., San Foo M., Green M. D., Whybourne A. M., Krozowski Z. S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature. 1980 Nov 20;288(5788):273–275. doi: 10.1038/288273a0. [DOI] [PubMed] [Google Scholar]
  11. Sutherland R. L., Murphy L. C. The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer. 1980 Sep;16(9):1141–1148. doi: 10.1016/0014-2964(80)90172-3. [DOI] [PubMed] [Google Scholar]
  12. Swartzendruber D. E. A bromodeoxyuridine (BUdR)-mithramycin technique for detecting cycling and non-cycling cells by flow microfluorometry. Exp Cell Res. 1977 Oct 15;109(2):439–443. doi: 10.1016/0014-4827(77)90024-6. [DOI] [PubMed] [Google Scholar]
  13. Vindeløv L. L., Christensen I. J., Jensen G., Nissen N. I. Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry. 1983 Mar;3(5):332–339. doi: 10.1002/cyto.990030505. [DOI] [PubMed] [Google Scholar]
  14. Vindeløv L. L., Christensen I. J., Keiding N., Spang-Thomsen M., Nissen N. I. Long-term storage of samples for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):317–322. doi: 10.1002/cyto.990030502. [DOI] [PubMed] [Google Scholar]
  15. Vindeløv L. L., Christensen I. J., Nissen N. I. Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry. 1983 Mar;3(5):328–331. doi: 10.1002/cyto.990030504. [DOI] [PubMed] [Google Scholar]
  16. Winneker R. C., Clark J. H. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver. Endocrinology. 1983 Jun;112(6):1910–1915. doi: 10.1210/endo-112-6-1910. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES